534
Participants
Start Date
August 31, 2015
Primary Completion Date
March 31, 2019
Study Completion Date
March 31, 2019
Not applicable - no defined intervention
Participants who received at least one injection of RBP-6000 or placebo and either withdrew from or completed the Phase III clinical program which included studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003) were eligible for the RECOVER Study.
Amit Vijapura, Jacksonville
Winston Technology Research LLC, Haleyville
Boyett Health Services, Hamilton
Oklahoma Clinical Research Center, Oklahoma City
Pahl Pharmaceutical Professionals, Oklahoma City
InSite Clinical Research, DeSoto
Pillar Clinic Research, LLC, Dallas
Altea Research Institute, Las Vegas
Collaborative Neuroscience Networks, Inc., Long Beach
Woodland International Research Group, Little Rock
Behavioral Research Specialists, Glendale
Synergy Research Center, National City
North County Clinical Research, Oceanside
Artemis Institute for Clinical Research, San Diego
Meridien Research, Lakeland
Try Research, Maitland
Innovative Clinical Research, Miami
Scientific Clinical Research, Miami
Research Centers of America, Oakland Park
Louisiana Research Associates, New Orleans
Louisiana Clinical Research, Shreveport
Stanley Street Treatment and Resources, Fall River
Precise Research Centers, Inc., Flowood
St. Louis Clinical Trials, St Louis
The Medical Research Network, LLC, New York
Neuro-behavioral Clinical Research, Canton
Midwest Clinical Research Center, Dayton
Charak Clinical Research Center, Garfield Heights
CODA, Portland
Tipton Medical and Diagnostic Center aka Clinical Research Associates of Central PA, Altoona
UPenn Treatment Research Center, Philadelphia
Carolina Clinical Trials, Charleston
Adams Clinical Trials, Watertown
Hassman Research Institute, Berlin
Center for Emotional Fitness, Cherry Hill
Lead Sponsor
Indivior Inc.
INDUSTRY